Your biotech website is not a brochure that exists to inform. It is a credibility instrument that exists to make the right people want to know more. Build it for that job, not for comprehensiveness.
What a Pre-Commercial Biotech Website Must Do
A pre-commercial biotech company website operates in a fundamentally different mode from a commercial website. It has no products to sell, no patients to acquire, and no prescribers to convert. Its primary job is to build the credibility and conviction of three audiences: investors evaluating whether to fund, talent evaluating whether to join, and partners evaluating whether to engage.
Each of these audiences visits the website with a specific evaluative question. The investor is asking: "Is this company real, serious, and led by people who can execute?" The talent candidate is asking: "Is this a place where serious work is done and where I would be proud to work?" The partner is asking: "Do these people know what they are doing scientifically, and is it worth a conversation?"
According to research by STAT News on biotech investor behavior (2024), 91% of biotech investors say they conduct an independent website review before responding to unsolicited outreach from an unknown company. A poorly designed or under-developed website is the single most common reason cited for not responding to an otherwise interesting pitch email.
The website's job is not to replace the pitch deck or the partnership discussion. It is to answer the basic credibility questions convincingly enough that the investor or partner responds to the outreach and takes the next step.
The Five Pages Every Biotech Website Needs
The Home Page must communicate mission and identity within the first scroll. The home page visitor should be able to answer three questions without clicking anywhere else: what does this company do, what stage is it at, and who is behind it. The headline must be a plain-language statement of the company's mission, not a slogan. A biotech home page headline that says "Transforming the future of medicine" communicates nothing. A headline that says "Developing first-in-class RNA therapies for inherited cardiomyopathies" communicates specifically and credibly. The Science or Platform Page is where the scientific substance lives. This page serves the detail-seeking investor, the scientific partner, and the academic collaborator who want to understand the mechanism, the approach, and the evidence. It should contain enough scientific substance to satisfy a technically sophisticated reader while being structured so that a non-specialist can follow the narrative logic without getting lost in the mechanism details. The Pipeline Page communicates the company's current programs and their development stage. For pre-clinical companies, this page shows the planned development pathway and the scientific rationale for the target selection. For companies with clinical programs, it shows clinical stage, indication, and key upcoming milestones. The pipeline page is the page that investors, financial journalists, and analysts check most frequently after initial discovery, and it must be kept current. The Team Page must communicate not just who the team members are, but why this team is the right team for this particular program. Generic credentials (PhD from MIT, ten years in pharma) are expected. The narrative that explains what unique combination of experience and insight this specific team brings to this specific problem is what distinguishes a team page that builds conviction from one that merely confirms that qualified people are involved. The News or Publications Page demonstrates that the company is active, progressing, and visible in the scientific and business community. A news page that has not been updated in eighteen months is a negative signal. A page showing recent publications, conference presentations, partnerships, and funding milestones tells the story of a company that is moving forward.
Common Biotech Website Design Failures
The underdeveloped placeholder site. Many early-stage biotech companies launch with a site that consists of a logo, a one-paragraph company description, and a contact form. The reasoning is that the company is not yet ready to share detailed information. The result is that every investor or partner who visits the site forms the impression that the company does not take its own communications seriously. A minimal but complete website (five to seven pages, each doing a specific job) is always better than an incomplete placeholder. The science-first home page. The home page that opens with a mechanism of action diagram or a pipeline table is speaking to a scientific audience at the expense of every other audience. The investor who does not have a PhD biochemistry background will not know how to interpret the diagram and will not stay to figure it out. Mission first, science available for those who want it. The outdated team page. A team page that lists scientific advisors who left the company, board members who resigned, or a team composition that is significantly different from the current reality is a credibility problem. An investor who conducts LinkedIn due diligence and finds significant differences between the website team list and the LinkedIn profiles of team members will question the accuracy of everything else on the site. No clear navigation for different audiences. A well-designed biotech website acknowledges that it is serving multiple audiences with different needs and provides clear navigation pathways for each. Investor section, science section, careers section, and news section with clear labeling allow each audience to find what they came for without having to search.
Comparison Table: Low-Performance vs. High-Performance Biotech Website
Element | Low-Performance | High-Performance |
|---|---|---|
Home headline | Generic tagline | Mission-specific, plain language |
Science content | Minimal or inaccessible | Layered: narrative then detail |
Pipeline | Absent or outdated | Current, milestone-specific |
Team page | Generic bios | Narrative of specific qualification |
News | Infrequent or absent | Regular updates, conference presence |
Mobile optimization | Desktop-only design | Mobile-first responsive |
Contact | Generic email only | Investor, partner, media, careers paths |
Update frequency | Annually | Quarterly minimum |
The Technical Requirements for Biotech Website Design
Biotech websites must meet technical standards that align with the expectations of sophisticated professional audiences.
Performance. A site that loads slowly communicates disorganization. According to Google's 2024 Web Performance data, 53% of mobile users abandon a page that takes longer than three seconds to load. For a biotech company whose website audience is highly sophisticated and time-pressed, a slow-loading site is a brand failure. Mobile optimization. The majority of initial website visits from conference contacts and investor outreach follow-ups happen on mobile devices. A site that is not properly optimized for mobile display communicates that the company built its digital presence without thinking about how its primary audiences actually access it. SSL security. Every biotech website must use HTTPS. An unsecured site triggers browser security warnings that damage the credibility the site is designed to build. ADA compliance. The website should meet WCAG 2.1 AA accessibility standards. This is both a legal requirement in the US and UK markets and an ethical commitment that the company's communications are accessible to everyone, including people with visual impairments or other accessibility needs.
Content Update Strategy for Biotech Websites
A biotech website that is not updated regularly becomes a liability. The company's scientific progress, team composition, funding status, and partnership landscape all change over time, and a website that does not reflect current reality creates a credibility gap between the website impression and the reality that investors and partners discover in due diligence.
The minimum update cadence for a biotech website is quarterly for the news and pipeline sections, and immediately on any significant milestone (funding close, clinical data readout, new partnership, new team member at the leadership level). The team and science pages should be reviewed semi-annually and updated to reflect any significant changes.
Internal Links
Biotech companies building a complete digital and physical brand presence should review biotech company branding for the foundational brand strategy that should precede website design. The visual identity system that the website should express is covered in life sciences brand identity. Companies preparing for investor meetings alongside the website launch should also review biotech pitch deck design.
FAQ: Biotech Website Design
Q: How much should a biotech company spend on its website?
A: Early-stage (pre-Series A) biotech companies typically invest between $15,000 and $40,000 in a professionally designed website. This range covers design, development, content writing, and initial SEO. Post-Series A companies with more complex content requirements typically invest $40,000 to $100,000. The website is the company's permanent public face and its primary credibility instrument: underinvesting in it is a strategic error.
Q: Should a biotech company have a patient-facing website section?
A: It depends on the stage and the indication. Pre-commercial biotech companies with programs in conditions affecting significant patient populations can benefit from a patient-information section that explains the research in plain language, provides information about clinical trial participation, and demonstrates the company's connection to the patient community it is working to serve. This section must be carefully written to avoid any suggestion of promotional communication about a product that has not been approved.
Q: How important is SEO for a biotech company website?
A: More important than most biotech companies recognize. Investors, journalists, and potential partners who encounter the company's name will search for it. A website that does not appear prominently in searches for the company name or for the indication and mechanism keywords the company operates in is missing organic discovery opportunities. Basic SEO: proper page titles and meta descriptions, consistent use of the company name and key scientific terms, clean site architecture, and fast loading times are the minimum standard.
Q: Should biotech company websites have a blog or news section?
A: Yes. Regular content updates, even brief ones covering conference presentations, publication citations, and team milestones, signal an active and progressing company. A news section also provides SEO value by creating indexed pages with relevant keyword content. The minimum publishing cadence is monthly, with brief updates rather than long-form articles for companies with limited communications resources.
Q: How do you handle confidential pipeline information on a public website?
A: By making strategic choices about what to disclose publicly and what to reserve for due diligence conversations. The website should be honest about the existence of programs that have been publicly disclosed or that are visible in clinical trial registries. Programs that are genuinely confidential do not need to be disclosed. The error to avoid is describing the pipeline in terms vague enough to satisfy a confidentiality concern but too vague to communicate what the company is actually working on.
I am Tambi Haşpak, a brand strategist and creative director with an unfair advantage: I am a pharmacist. I run a creative studio for cosmetics, supplements and beyond. Seventeen years in this category. Exclusively.
